{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:10:40Z","timestamp":1790032240576,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["4RF1AG055549-03"],"award-info":[{"award-number":["4RF1AG055549-03"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["4RF1AG055549-03"],"award-info":[{"award-number":["4RF1AG055549-03"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG061359, U19AG063744, R01AG069901, U19AG074879, U01AG088562, R01AG081322"],"award-info":[{"award-number":["U01AG061359, U19AG063744, R01AG069901, U19AG074879, U01AG088562, R01AG081322"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["U19AG063744, U01AG061359, R01AG081322"],"award-info":[{"award-number":["U19AG063744, U01AG061359, R01AG081322"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10474-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:26:51Z","timestamp":1781080011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Purba","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-2860","authenticated-orcid":false,"given":"Eugenia","family":"Trushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-0923","authenticated-orcid":false,"given":"Matthias","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1858-5732","authenticated-orcid":false,"given":"Rima","family":"Kaddurah-Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-4941","authenticated-orcid":false,"given":"Priyanka","family":"Baloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"10474_CR1","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack","year":"2019","unstructured":"Jack, C. R. et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321, 2316 (2019).","journal-title":"JAMA"},{"key":"10474_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41593-018-0289-8","volume":"22","author":"MA Busche","year":"2019","unstructured":"Busche, M. A. et al. Tau impairs neural circuits, dominating amyloid-\u03b2 effects, in Alzheimer models in vivo. Nat. Neurosci. 22, 57\u201364 (2019).","journal-title":"Nat. Neurosci."},{"key":"10474_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/alzrt278","volume":"6","author":"E Kontsekova","year":"2014","unstructured":"Kontsekova, E., Zilka, N., Kovacech, B., Novak, P. & Novak, M. First-in-man tau vaccine targeting structural determinants essential for pathological tau\u2013tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model. Alzheimers Res. Ther. 6, 44 (2014).","journal-title":"Alzheimers Res. Ther."},{"key":"10474_CR4","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier, S. et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873\u20132884 (2016).","journal-title":"Lancet"},{"key":"10474_CR5","doi-asserted-by":"publisher","unstructured":"Vakani, A. & Sharma, G. Identification of Inhibitors for Amyloid-beta in Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy. Preprint at https:\/\/doi.org\/10.26434\/chemrxiv-2024-z4k0k (2024).","DOI":"10.26434\/chemrxiv-2024-z4k0k"},{"key":"10474_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","volume":"10","author":"A-M Lacosta","year":"2018","unstructured":"Lacosta, A.-M. et al. Safety, tolerability and immunogenicity of an active anti-A\u03b240 vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res. Ther. 10, 12 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"10474_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/alzrt82","volume":"3","author":"R Vassar","year":"2011","unstructured":"Vassar, R. & Kandalepas, P. C. The \u03b2-secretase enzyme BACE1 as a therapeutic target for Alzheimer\u2019s disease. Alzheimers Res. Ther. 3, 20 (2011).","journal-title":"Alzheimers Res. Ther."},{"key":"10474_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 311\u2013321 (2014).","journal-title":"N. Engl. J. Med."},{"key":"10474_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/alz.12235","volume":"17","author":"MN Sabbagh","year":"2021","unstructured":"Sabbagh, M. N. & Cummings, J. Open peer commentary to \u201cfailure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by biogen december 2019\u201d. Alzheimer\u2019s. Dement. 17, 702\u2013703 (2021).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"10474_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-med-051022-043645","volume":"75","author":"JL Heidebrink","year":"2024","unstructured":"Heidebrink, J. L. & Paulson, H. L. Lessons learned from approval of aducanumab for Alzheimer\u2019s disease. Annu. Rev. Med. 75, 99\u2013111 (2024).","journal-title":"Annu. Rev. Med."},{"key":"10474_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"10474_CR12","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1093\/brain\/awt171","volume":"136","author":"BG Perez-Nievas","year":"2013","unstructured":"Perez-Nievas, B. G. et al. Dissecting phenotypic traits linked to human resilience to Alzheimer\u2019s pathology. Brain 136, 2510\u20132526 (2013).","journal-title":"Brain"},{"key":"10474_CR13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awv048","volume":"138","author":"MA Parra","year":"2015","unstructured":"Parra, M. A. et al. Memory binding and white matter integrity in familial Alzheimer\u2019s disease. Brain 138, 1355\u20131369 (2015).","journal-title":"Brain"},{"key":"10474_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41593-021-00999-y","volume":"25","author":"ECB Johnson","year":"2022","unstructured":"Johnson, E. C. B. et al. Large-scale deep multi-layer analysis of Alzheimer\u2019s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat. Neurosci. 25, 213\u2013225 (2022).","journal-title":"Nat. Neurosci."},{"key":"10474_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-024-01760-9","volume":"12","author":"LE de Vries","year":"2024","unstructured":"de Vries, L. E. et al. Gene-expression profiling of individuals resilient to Alzheimer\u2019s disease reveals higher expression of genes related to metallothionein and mitochondrial processes and no changes in the unfolded protein response. Acta Neuropathol. Commun. 12, 68 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"10474_CR16","doi-asserted-by":"crossref","unstructured":"Higginbotham, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease. Sci. Adv. 6, eaaz9360 (2020).","DOI":"10.1212\/WNL.94.15_supplement.4738"},{"key":"10474_CR17","doi-asserted-by":"publisher","first-page":"102747","DOI":"10.1016\/j.conb.2023.102747","volume":"81","author":"G L\u00f3pez-Dom\u00e9nech","year":"2023","unstructured":"L\u00f3pez-Dom\u00e9nech, G. & Kittler, J. T. Mitochondrial regulation of local supply of energy in neurons. Curr. Opin. Neurobiol. 81, 102747 (2023).","journal-title":"Curr. Opin. Neurobiol."},{"key":"10474_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40035-024-00409-w","volume":"13","author":"N Song","year":"2024","unstructured":"Song, N., Mei, S., Wang, X., Hu, G. & Lu, M. Focusing on mitochondria in the brain: from biology to therapeutics. Transl. Neurodegener. 13, 23 (2024).","journal-title":"Transl. Neurodegener."},{"key":"10474_CR19","doi-asserted-by":"publisher","unstructured":"Rivlin, P. K. et al. Connectomic analysis of mitochondria in the central brain of Drosophila. Preprint at https:\/\/doi.org\/10.1101\/2024.04.21.590464 (2024).","DOI":"10.1101\/2024.04.21.590464"},{"key":"10474_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.neuron.2017.09.055","volume":"96","author":"T Misgeld","year":"2017","unstructured":"Misgeld, T. & Schwarz, T. L. Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron 96, 651\u2013666 (2017).","journal-title":"Neuron"},{"key":"10474_CR21","doi-asserted-by":"publisher","first-page":"8493","DOI":"10.1074\/jbc.M110.163824","volume":"286","author":"M Tiwari","year":"2011","unstructured":"Tiwari, M., Lopez-Cruzan, M., Morgan, W. W. & Herman, B. Loss of caspase-2-dependent apoptosis induces autophagy after mitochondrial oxidative stress in primary cultures of young adult cortical neurons. J. Biol. Chem. 286, 8493\u20138506 (2011).","journal-title":"J. Biol. Chem."},{"key":"10474_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1326-9-16","volume":"9","author":"L Kukreja","year":"2014","unstructured":"Kukreja, L., Kujoth, G. C., Prolla, T. A., Van Leuven, F. & Vassar, R. Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP\/Ld transgenic mouse model of Alzheimer\u2019s disease. Mol. Neurodegener. 9, 16 (2014).","journal-title":"Mol. Neurodegener."},{"key":"10474_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cns.12655","volume":"23","author":"M Golpich","year":"2017","unstructured":"Golpich, M. et al. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci. Ther. 23, 5\u201322 (2017).","journal-title":"CNS Neurosci. Ther."},{"key":"10474_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-024-00719-7","volume":"19","author":"LE de Vries","year":"2024","unstructured":"de Vries, L. E., Huitinga, I., Kessels, H. W., Swaab, D. F. & Verhaagen, J. The concept of resilience to Alzheimer\u2019s Disease: current definitions and cellular and molecular mechanisms. Mol. Neurodegener. 19, 33 (2024).","journal-title":"Mol. Neurodegener."},{"key":"10474_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.tins.2022.02.005","volume":"45","author":"SM Neuner","year":"2022","unstructured":"Neuner, S. M. et al. Translational approaches to understanding resilience to Alzheimer\u2019s disease. Trends Neurosci. 45, 369\u2013383 (2022).","journal-title":"Trends Neurosci."},{"key":"10474_CR26","doi-asserted-by":"publisher","unstructured":"Pagano Zottola, A. C. et al. Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice. Nat. Neurosci. https:\/\/doi.org\/10.1038\/s41593-025-02032-y (2025).","DOI":"10.1038\/s41593-025-02032-y"},{"key":"10474_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield, D. A. & Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 20, 148\u2013160 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"10474_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s42003-020-1079-x","volume":"3","author":"TC Hammond","year":"2020","unstructured":"Hammond, T. C. et al. \u03b2-amyloid and tau drive early Alzheimer\u2019s disease decline while glucose hypometabolism drives late decline. Commun. Biol. 3, 352 (2020).","journal-title":"Commun. Biol."},{"key":"10474_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01927-x","volume":"15","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Coupling relationship between glucose and oxygen metabolisms to serve as an imaging biomarker for Alzheimer\u2019s disease. Sci. Rep. 15, 16838 (2025).","journal-title":"Sci. Rep."},{"key":"10474_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.70180","volume":"46","author":"S Soltani","year":"2025","unstructured":"Soltani, S. et al. Relationships between brain glucose metabolism patterns and impaired glycemic status: a systematic review of FDG-PET studies with a focus on Alzheimer\u2019s disease. Hum. Brain Mapp. 46, e70180 (2025).","journal-title":"Hum. Brain Mapp."},{"key":"10474_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57032-0","volume":"16","author":"M Arnold","year":"2025","unstructured":"Arnold, M. et al. Individual bioenergetic capacity as a potential source of resilience to Alzheimer\u2019s disease. Nat. Commun. 16, 1910 (2025).","journal-title":"Nat. Commun."},{"key":"10474_CR32","doi-asserted-by":"crossref","unstructured":"Borkowski, K. et al. APOE genotype influences on the brain metabolome of aging mice\u2013role for mitochondrial energetics in mechanisms of resilience in APOE2 genotype. Mol. Neurodegener. 20, 97 (2025).","DOI":"10.1186\/s13024-025-00888-z"},{"key":"10474_CR33","doi-asserted-by":"crossref","unstructured":"Britton, J. S. et al. Agora: an open science platform that enables evidence-based exploration of Alzheimer\u2019s Disease therapeutic targets. Alzheimer\u2019s Dement. 21, e098626 (2025).","DOI":"10.1002\/alz70855_098626"},{"key":"10474_CR34","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.cell.2023.08.039","volume":"186","author":"H Mathys","year":"2023","unstructured":"Mathys, H. et al. Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer\u2019s disease pathology. Cell 186, 4365\u20134385.e27 (2023).","journal-title":"Cell"},{"key":"10474_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19622-y","volume":"11","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee, S. et al. Molecular estimation of neurodegeneration pseudotime in older brains. Nat. Commun. 11, 5781 (2020).","journal-title":"Nat. Commun."},{"key":"10474_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36519-8","volume":"14","author":"H Park","year":"2023","unstructured":"Park, H. et al. Single-cell RNA-sequencing identifies disease-associated oligodendrocytes in male APP NL-G-F and 5XFAD mice. Nat. Commun. 14, 802 (2023).","journal-title":"Nat. Commun."},{"key":"10474_CR37","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/j.neuron.2021.06.010","volume":"109","author":"V Kellner","year":"2021","unstructured":"Kellner, V. et al. Dual metabotropic glutamate receptor signaling enables coordination of astrocyte and neuron activity in developing sensory domains. Neuron 109, 2545\u20132555.e7 (2021).","journal-title":"Neuron"},{"key":"10474_CR38","doi-asserted-by":"crossref","unstructured":"Jiang, W. et al. CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in autoimmune-mediated neuroinflammation. Sci. Adv. 9 (2023).","DOI":"10.1126\/sciadv.adg8148"},{"key":"10474_CR39","doi-asserted-by":"publisher","unstructured":"Ulmer, M. A. et al. An integrated molecular atlas of Alzheimer\u2019s disease. Preprint at https:\/\/doi.org\/10.1101\/2021.09.14.21263565 (2026).","DOI":"10.1101\/2021.09.14.21263565"},{"key":"10474_CR40","doi-asserted-by":"publisher","unstructured":"Cetra Antunes, B. et al. Mitochondria at synapse utilize fatty acids as a bioenergetic fuel source. Preprint at https:\/\/doi.org\/10.1101\/2025.05.26.656116 (2025).","DOI":"10.1101\/2025.05.26.656116"},{"key":"10474_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s10555-024-10216-4","volume":"43","author":"JM Bacon","year":"2024","unstructured":"Bacon, J. M., Jones, J. L., Liu, G.-S., Dickinson, J. L. & Raspin, K. Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets. Cancer Metastasis Rev. 43, 1119\u20131135 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"10474_CR42","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.cell.2024.04.037","volume":"187","author":"A Suomalainen","year":"2024","unstructured":"Suomalainen, A. & Nunnari, J. Mitochondria at the crossroads of health and disease. Cell 187, 2601\u20132627 (2024).","journal-title":"Cell"},{"key":"10474_CR43","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s007020070011","volume":"107","author":"M Rainer","year":"2000","unstructured":"Rainer, M., Kraxberger, E., Haushofer, M., Mucke, H. A. & Jellinger, K. A. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J. Neural Transm. 107, 1475\u20131481 (2000).","journal-title":"J. Neural Transm."},{"key":"10474_CR44","first-page":"27","volume":"30","author":"V Demarin","year":"2004","unstructured":"Demarin, V., Podobnik, S. S., Storga-Tomic, D. & Kay, G. Treatment of Alzheimer\u2019s disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs Exp. Clin. Res. 30, 27\u201333 (2004).","journal-title":"Drugs Exp. Clin. Res."},{"key":"10474_CR45","first-page":"1","volume":"26","author":"JG Birkmayer","year":"1996","unstructured":"Birkmayer, J. G. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann. Clin. Lab. Sci. 26, 1\u20139 (1996).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10474_CR46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1089\/ars.2023.0354","volume":"39","author":"K Yaku","year":"2023","unstructured":"Yaku, K. & Nakagawa, T. N. A. D. + Precursors in human health and disease: current status and future prospects. Antioxid. Redox Signal. 39, 1133\u20131149 (2023).","journal-title":"Antioxid. Redox Signal."},{"key":"10474_CR47","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.14336\/AD.2021.0523","volume":"12","author":"J She","year":"2021","unstructured":"She, J., Sheng, R. & Qin, Z.-H. Pharmacology and potential implications of nicotinamide adenine dinucleotide precursors. Aging Dis. 12, 1879 (2021).","journal-title":"Aging Dis."},{"key":"10474_CR48","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. NAD+ in Alzheimer\u2019s disease: molecular mechanisms and systematic therapeutic evidence obtained in vivo. Front. Cell Dev. Biol. 9, 668491 (2021).","DOI":"10.3389\/fcell.2021.668491"},{"key":"10474_CR49","doi-asserted-by":"publisher","unstructured":"D\u00f6lle, C. & Tzoulis, C. NAD augmentation as a disease-modifying strategy for neurodegeneration. Trends Endocrinol. Metab. https:\/\/doi.org\/10.1016\/j.tem.2025.03.013 (2025).","DOI":"10.1016\/j.tem.2025.03.013"},{"key":"10474_CR50","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.tig.2024.11.010","volume":"41","author":"K Yen","year":"2025","unstructured":"Yen, K., Miller, B., Kumagai, H., Silverstein, A. & Cohen, P. Mitochondrial-derived microproteins: from discovery to function. Trends Genet. 41, 132\u2013145 (2025).","journal-title":"Trends Genet."},{"key":"10474_CR51","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41380-023-02344-0","volume":"29","author":"S-J Kim","year":"2024","unstructured":"Kim, S.-J. et al. A naturally occurring variant of SHLP2 is a protective factor in Parkinson\u2019s disease. Mol. Psychiatry 29, 505\u2013517 (2024).","journal-title":"Mol. Psychiatry"},{"key":"10474_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40082-7","volume":"14","author":"SK Kim","year":"2023","unstructured":"Kim, S. K. et al. Mitochondria-derived peptide SHLP2 regulates energy homeostasis through the activation of hypothalamic neurons. Nat. Commun. 14, 4321 (2023).","journal-title":"Nat. Commun."},{"key":"10474_CR53","doi-asserted-by":"publisher","unstructured":"Miller, B. et al. Mitochondrial DNA variation in Alzheimer\u2019s disease reveals a unique microprotein called SHMOOSE. Mol. Psychiatry, https:\/\/doi.org\/10.1038\/s41380-022-01769-3 (2022).","DOI":"10.1038\/s41380-022-01769-3"},{"key":"10474_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14153","volume":"23","author":"B Miller","year":"2024","unstructured":"Miller, B. et al. Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4-induced brain pathology. Aging Cell 23, e14153 (2024).","journal-title":"Aging Cell"},{"key":"10474_CR55","doi-asserted-by":"publisher","first-page":"D1541","DOI":"10.1093\/nar\/gkaa1011","volume":"49","author":"S Rath","year":"2021","unstructured":"Rath, S. et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 49, D1541\u2013D1547 (2021).","journal-title":"Nucleic Acids Res."},{"key":"10474_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Random forests. Mach. Learn. 45, 5\u201332 (2001).","journal-title":"Mach. Learn."},{"key":"10474_CR57","doi-asserted-by":"crossref","unstructured":"Friedman, J. H. Greedy function approximation: a gradient boosting machine. Ann. Stat. 29, 1189\u20131232 (2001).","DOI":"10.1214\/aos\/1013203451"},{"key":"10474_CR58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1023\/A:1012487302797","volume":"46","author":"I Guyon","year":"2002","unstructured":"Guyon, I., Weston, J., Barnhill, S. & Vapnik, V. Gene selection for cancer classification using support vector machines. Mach. Learn. 46, 389\u2013422 (2002).","journal-title":"Mach. Learn."},{"key":"10474_CR59","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B Stat. Methodol. 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"10474_CR60","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41586-024-07606-7","volume":"632","author":"H Mathys","year":"2024","unstructured":"Mathys, H. et al. Single-cell multiregion dissection of Alzheimer\u2019s disease. Nature 632, 858\u2013868 (2024).","journal-title":"Nature"},{"key":"10474_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0844-5","volume":"16","author":"G Finak","year":"2015","unstructured":"Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).","journal-title":"Genome Biol."},{"key":"10474_CR62","doi-asserted-by":"publisher","unstructured":"Mandal, P., & Baloni, P. Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer\u2019s disease. Preprint at Zenodo https:\/\/doi.org\/10.5281\/zenodo.19633113 (2026).","DOI":"10.5281\/zenodo.19633113"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10474-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:39:45Z","timestamp":1790030385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10474-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10474"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10474-8","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.T. is a co-inventor of four U.S. Patents, 11,161,814; 10,336,700; 10,774,045; and 12,017,992, which are relevant to the development of mitochondria-targeted therapeutics. She and the Mayo Clinic own the IP on this technology. R.K.D. is an inventor on a series of patents on the use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia, and Metabosensor. M.A. is a co-inventor (through Duke University\/Helmholtz Zentrum M\u00fcnchen) on patents on applications of metabolomics in diseases of the central nervous system; M.A. holds equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in depression. The remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1233"}}